Rezolve AI enters July with short sellers caught between a stock that just rallied 22% in a week and a borrow market that has never been more hostile.
The week's defining move was the $300M buyback approval, which triggered a 21% single-session gain on June 30 and carried the stock to $3.15. That price recovery matters for shorts in a specific way: those who rebuilt positions around the June 26 earnings print at lower prices are now underwater, paying 200% APR to stay in the trade. The cost to borrow crossed that threshold on June 30 — the first time in the tracked history of this stock — and the trajectory tells its own story. In late May, borrow costs ran around 13–15%. By the end of June they had multiplied roughly fourteen-fold. That is not a gradual drift; it is a compression event in the lending market.
The broader positioning picture is tense but not uniformly bearish. Short interest has actually eased slightly from its mid-week peak: roughly 50 million shares were on loan on June 25, and that figure has since pulled back to about 45.9 million, or 15.2% of free float. Availability has loosened fractionally from the truly extreme levels seen on June 12 — when it briefly touched 0.07%, effectively meaning no shares were left in the lending pool — and now reads 11.4%. That is still very tight: roughly one share available for every eight already borrowed. The ORTEX short score sits at 84.5, near the top of the two-week range, reflecting the combined weight of elevated short interest, hostile borrow, and strong adverse price momentum for the short side. Peers moved in the opposite direction this week: fell 14.6% and dropped 15.9%, making RZLV's 22% gain look all the more isolated.
Options positioning offers a mild counterpoint to the squeeze narrative. The put/call ratio is running at 0.288, just a hair above its 20-day average of 0.27 and well within normal range — near the top of its 52-week band of 0.113–0.294, but only about one standard deviation above the mean. Options traders are not scrambling for downside protection, and they are not aggressively chasing calls into the rally either. The market in derivatives looks more like quiet watching than active conviction in either direction.
Insider activity adds a constructive note that predates the current squeeze. Founder and CEO Daniel Wagner bought roughly 813,000 shares across two April 2 transactions at $4.00, committing over $3.2 million of personal capital. A director added a further 95,600 shares in May at $2.78. Combined, net insider purchases over the 90-day window total more than $3.5 million — a meaningful signal from the people who know the business best, even if the current stock price at $3.15 is still well below Wagner's April entry.
The fundamental picture is complicated. Revenue growth is exceptional — the stock score note flagged a 1,058% year-on-year sales increase driving a growth score of 90 — but quality and value metrics remain deeply negative. EV/EBITDA is running at –266, and free cash flow is negative. The company is in heavy reinvestment mode, and profitability timelines are the central bear case. The buyback approval at $2.60 signals that management believes the stock is materially undervalued, but the mechanics of executing a $300M buyback against a tight lending market and 15% short interest will be closely scrutinised.
The next hard date is July 30, when Q2 results are due — and with short sellers still carrying a significant position at 200% borrow costs, the distance between now and that print is where the real test of conviction on both sides plays out.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
